These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31264148)

  • 1. Role of boost radiotherapy for local control of pure ductal carcinoma in situ after breast-conserving surgery: a multicenter, retrospective study of 622 patients.
    Cambra MJ; Moreno F; Sanz X; Anglada L; Mollà M; Reyes V; Arenas M; Pedro A; Ballester R; García V; Casals J; Cusidó M; Jimenez C; Escribà JM; Macià M; Solé JM; Arcusa A; Seguí MA; Gonzalez S; Farrús B; Biete A
    Clin Transl Oncol; 2020 May; 22(5):670-680. PubMed ID: 31264148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy.
    Moran MS; Zhao Y; Ma S; Kirova Y; Fourquet A; Chen P; Hoffman K; Hunt K; Wong J; Halasz LM; Freedman G; Prosnitz R; Yassa M; Nguyen DHA; Hijal T; Haffty BG; Wai ES; Truong PT
    JAMA Oncol; 2017 Aug; 3(8):1060-1068. PubMed ID: 28358936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy.
    Freedman G; Fowble B; Hanlon A; Nicolaou N; Fein D; Hoffman J; Sigurdson E; Boraas M; Goldstein L
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1005-15. PubMed ID: 10421533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
    Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
    JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation.
    Ono Y; Yoshimura M; Hirata K; Yamauchi C; Toi M; Suzuki E; Takada M; Hiraoka M; Mizowaki T
    Radiat Oncol; 2019 Jul; 14(1):121. PubMed ID: 31291997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Margin width and local recurrence after breast conserving surgery for ductal carcinoma in situ.
    Ekatah GE; Turnbull AK; Arthur LM; Thomas J; Dodds C; Dixon JM
    Eur J Surg Oncol; 2017 Nov; 43(11):2029-2035. PubMed ID: 28917445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.
    Miller ME; Muhsen S; Zabor EC; Flynn J; Olcese C; Giri D; Van Zee KJ; Pilewskie M
    Ann Surg Oncol; 2019 Dec; 26(13):4317-4325. PubMed ID: 31552614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of boost radiotherapy in early invasive ductal breast cancer with ductal carcinoma in situ component under negative surgical margins.
    Shimizu N; Myojin M; Tamura M; Nishiyama N; Yamashiro K; Yuyama Y; Okazaki Y; Suzuki Y; Takahashi M
    J Radiat Res; 2022 Jan; 63(1):80-87. PubMed ID: 34718690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma.
    Leong C; Boyages J; Jayasinghe UW; Bilous M; Ung O; Chua B; Salisbury E; Wong AY
    Cancer; 2004 May; 100(9):1823-32. PubMed ID: 15112262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
    Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
    Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins.
    Suzuki R; Yoshida M; Oguchi M; Yoshioka Y; Tokumasu K; Osako T; Ono S; Ueno T; Miyagi Y
    J Radiat Res; 2020 May; 61(3):440-446. PubMed ID: 32163143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
    Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast-conserving treatment for ductal carcinoma in situ: Impact of boost and tamoxifen on local recurrences.
    Cutuli B; Wiezzane N; Palumbo I; Barbieri P; Guenzi M; Huscher A; Borghesi S; Delva C; Iannone T; Vianello E; Rosetto ME; Aristei C
    Cancer Radiother; 2016 Jun; 20(4):292-8. PubMed ID: 27344537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is higher dose radiation necessary for positive resection margin after breast-conserving surgery for breast cancer?
    Cho WK; Choi DH; Park W; Kim H; Cha H
    Breast; 2019 Oct; 47():16-21. PubMed ID: 31265973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of escalating the boost dose for patients with involved resection margin after breast-conserving surgery.
    Park S; Ahn SD; Choi EK; Kim SS
    Jpn J Clin Oncol; 2018 Mar; 48(3):272-277. PubMed ID: 29385496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Whelan TJ; Julian JA; Berrang TS; Kim DH; Germain I; Nichol AM; Akra M; Lavertu S; Germain F; Fyles A; Trotter T; Perera FE; Balkwill S; Chafe S; McGowan T; Muanza T; Beckham WA; Chua BH; Gu CS; Levine MN; Olivotto IA;
    Lancet; 2019 Dec; 394(10215):2165-2172. PubMed ID: 31813635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of clinical and pathologic features with outcome in patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy.
    Rodrigues N; Carter D; Dillon D; Parisot N; Choi DH; Haffty BG
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1331-5. PubMed ID: 12459354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
    Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML
    Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.